Property, Plant and Equipment Property, Plant and Equipment

9 Months Ended

Sep. 30, 2020

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,734.8 million and $1,590.9 million as of September 30, 2020 and December 31, 2019, respectively. For the three and nine months ended September 30, 2020, depreciation expense totaled $51.5 million and $151.2 million, respectively, compared to $45.5 million and $145.4 million, respectively, in the prior year comparative periods.

Solothurn, Switzerland Manufacturing Facility

In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of September 30, 2020 and December 31, 2019, we had approximately $1.8 billion and $1.9 billion, respectively, capitalized as construction in progress related to this facility. For the nine months ended September 30, 2020, we placed approximately $256.8 million of fixed assets in service related to this facility. As of September 30, 2020, we had contractual commitments of approximately $14.8 million outstanding related to the construction of this facility.